Literature DB >> 34674302

Painful diabetic peripheral neuropathy: Role of oxidative stress and central sensitisation.

Di Ye1, Timothy J Fairchild2, Lechi Vo1, Peter D Drummond1.   

Abstract

AIMS: Diabetic peripheral neuropathy (DPN) occurs in about half of people with diabetes, of whom a quarter may develop chronic pain. Pain may remain for years yet be difficult to treat because the underlying mechanisms remain unclear. There is consensus that processing excessive glucose leads to oxidative stress, interfering with normal metabolism. In this narrative review, we argue that oxidative stress may also contribute to pain.
METHODS: We reviewed literature in PubMed published between January 2005 and August 2021. RESULTS AND
CONCLUSIONS: In diabetes, hyperglycaemia and associated production of reactive species can directly increase pain signalling and activate sensory neurons; or the effects can be indirect, mediated by mitochondrial damage and enhanced inflammation. Furthermore, pain processing in the central nervous system is compromised in painful DPN. This is implicated in central sensitisation and dysfunctional pain modulation. However, central pain modulatory function is understudied in diabetes. Future research is required to clarify whether central sensitisation and/or disturbances in central pain modulation contribute to painful DPN. Positive results would facilitate early detection and future treatment.
© 2021 Diabetes UK.

Entities:  

Keywords:  central sensitisation; diabetic peripheral neuropathy; oxidative stress; pain; pain modulation

Mesh:

Year:  2021        PMID: 34674302     DOI: 10.1111/dme.14729

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  3 in total

1.  5-Oxopyrrolidine-3-carboxamides as Nav1.8 Inhibitors for Treating Pain Disorders, Cough Disorders, and Acute and Chronic Itch Disorders.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-04-14       Impact factor: 4.345

2.  2-Oxooxazolidine-5-carboxamides as Nav1.8 Inhibitors for Treating Pain Disorders, Cough Disorders, and Acute and Chronic Itch Disorders.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-03-01       Impact factor: 4.345

3.  Efficacy and safety of Mudan granules for painful diabetic peripheral neuropathy: A protocol for a double-blind randomized controlled trial.

Authors:  Aixia Zhang; Qian Wang; Min Liu; Mengxia Tan; Xiaodan Zhang; Raoping Wu
Journal:  Medicine (Baltimore)       Date:  2022-03-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.